Health‐related quality of life in multiple sclerosis: effects of natalizumab

Abstract

HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab.